Pharma Industrial India Magazine - July - August 2024

Q How does TechInvention ensure the quality, efficacy, and safety of the vaccines produced at the facility? Syed Ahmed: TechInvention is dedi- cated to helping clients maintain high standards through robust quality man- agement systems (QMS). By focusing on strict adherence to these systems, TechInvention ensures that clients’ op- erations align with stringent international guidelines. Supporting the formulation of Standard Operating Procedures (SOPs) is a key part of this, as SOPs help in consistently achieving compliance and maintaining quality across various pro- cesses. This approach is crucial for vaccines manufacturing where efficacy, safety, quality and reliability are of paramount importance. Q Can you discuss the role of auto- mation and digitalization in the new vaccine manufacturing facility? Syed Ahmed: Automation philosophy strengthened by digitalization enables a seamless co-ordination and integration of multiple functions including but not limited to Production (Upstream, Down- stream, Equipment), Warehousing Build- ing Management System (BMS), Envi- ronment Management System (EMS), Quality Assurance (QA) and Quality Control (QC). Digitalization facilitates in- tegration of the physical manufacturing functions through a digital interface like access and monitoring of manufacturing processes through devices like mobile phones, tabs etc. Together, automation and digitalization create a synergistic effect that not only streamlines operations but also ensures higher levels of compliance, quality, and operational efficiency. Q How does TechInvention ensure compliance with global standards and guidelines in vaccine manufacturing and what are the key challenges in set- ting up a cGMP-compliant vaccine man- ufacturing facility? Syed Ahmed: TechInvention emphasis- es on the significance of adhering to the International Conference on Harmoniza- tion (ICH) and World Health Organization (WHO) guidelines for biologics manufac- Syed Ahmed CEO, TechInvention TechInvention is committed to advancing vaccine technologies by continually developing and enhancing cutting-edge plat- forms, including recombinant protein, conjugate, OMV-based, and mRNA vaccines, states Syed Ahmed, CEO, TechInvention in his interview with Pharma Industrial India. PHARMA INDUSTRIALINDIA · JUL-AUG 24 12 INTEEWRSVIEW